BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31829266)

  • 1. Improving the relevance of randomised trials to primary care: a qualitative study investigating views towards pragmatic trials and the PRECIS-2 tool.
    Forbes G; Loudon K; Clinch M; Taylor SJC; Treweek S; Eldridge S
    Trials; 2019 Dec; 20(1):711. PubMed ID: 31829266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
    Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
    Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.
    Kalkman S; van Thiel GJ; Grobbee DE; Meinecke AK; Zuidgeest MG; van Delden JJ;
    Trials; 2016 Aug; 17(1):419. PubMed ID: 27550379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
    Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
    Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the applicability of results from primary care trials: lessons learned from applying PRECIS-2.
    Forbes G; Loudon K; Treweek S; Taylor SJC; Eldridge S
    J Clin Epidemiol; 2017 Oct; 90():119-126. PubMed ID: 28629699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
    Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
    Trials; 2016 Jan; 17():32. PubMed ID: 26772801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
    Thorpe KE; Zwarenstein M; Oxman AD; Treweek S; Furberg CD; Altman DG; Tunis S; Bergel E; Harvey I; Magid DJ; Chalkidou K
    J Clin Epidemiol; 2009 May; 62(5):464-75. PubMed ID: 19348971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An application of PRECIS-2 to evaluate trial design in a pilot cluster randomised controlled trial of a community-based smoking cessation intervention for women living in disadvantaged areas of Ireland.
    Darker C; Loudon K; O'Connell N; Castello S; Burke E; Vance J; Reynolds C; Buggy A; Dougall N; Williams P; Dobbie F; Bauld L; Hayes CB
    Pilot Feasibility Stud; 2022 Jan; 8(1):19. PubMed ID: 35078530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) model in clinical research: Application to refine a practice-based research network (PBRN) study.
    Elder WG; Munk N
    J Am Board Fam Med; 2014; 27(6):846-54. PubMed ID: 25381083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol.
    Nicholls SG; Carroll K; Brehaut J; Weijer C; Hey SP; Goldstein CE; Zwarenstein M; Graham ID; McKenzie JE; McIntyre L; Jairath V; Campbell MK; Grimshaw JM; Fergusson DA; Taljaard M
    BMC Med Ethics; 2018 Nov; 19(1):90. PubMed ID: 30458809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool.
    Ettori-Ajasse I; Tatin E; Forbes G; Eldridge S; Dibao-Dina C
    Trials; 2020 Mar; 21(1):281. PubMed ID: 32188470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
    Sharma T; Qamar I; Zwarenstein M
    J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRECIS-2 analysis of pragmatic acupuncture trials: a systematic review.
    Lim J; Lee H; Kim YS
    BMC Complement Med Ther; 2024 May; 24(1):181. PubMed ID: 38702632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders.
    Nicholls SG; Carroll K; Zwarenstein M; Brehaut JC; Weijer C; Hey SP; Goldstein CE; Graham ID; Grimshaw JM; McKenzie JE; Fergusson DA; Taljaard M;
    Trials; 2019 Dec; 20(1):765. PubMed ID: 31870433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research.
    Gaglio B; Phillips SM; Heurtin-Roberts S; Sanchez MA; Glasgow RE
    Implement Sci; 2014 Aug; 9():96. PubMed ID: 25163664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing a valid randomized pragmatic primary care implementation trial: the my own health report (MOHR) project.
    Krist AH; Glenn BA; Glasgow RE; Balasubramanian BA; Chambers DA; Fernandez ME; Heurtin-Roberts S; Kessler R; Ory MG; Phillips SM; Ritzwoller DP; Roby DH; Rodriguez HP; Sabo RT; Sheinfeld Gorin SN; Stange KC;
    Implement Sci; 2013 Jun; 8():73. PubMed ID: 23799943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials.
    Donovan JL; Paramasivan S; de Salis I; Toerien M
    Trials; 2014 Jan; 15():5. PubMed ID: 24393291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
    Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
    Trials; 2013 Apr; 14():115. PubMed ID: 23782862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.
    Selby P; Brosky G; Oh PI; Raymond V; Ranger S
    BMC Med Res Methodol; 2012 Jul; 12():101. PubMed ID: 22824225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.